PIT Study Design: Phase IB/II First Line Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS Wild-Type Patients with Metastatic Colorectal Cancer

被引：0
|
作者：
Price, T. [1 ,2 ,3 ,4 ]
Rico, G. Tapia [1 ]
Williams, J. [1 ]
Yeend, S. [1 ]
Lo, L. [1 ]
Patel, D. [1 ,2 ]
Tebbutt, N. [4 ,5 ]
Shapiro, J. [4 ,6 ]
Burge, M. [4 ,7 ]
Gebski, V. [3 ]
Townsend, A. [1 ,2 ,4 ]
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Univ Adelaide, Adelaide, SA, Australia
[3] NHMRC Clin Trials Ctr, Sydney Med Sch, Sydney, NSW, Australia
[4] AGITG, Sydney, NSW, Australia
[5] Austin Hlth, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
[7] Royal Brisbane Hosp, Brisbane, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
ORAL CHEMOTHERAPEUTIC-AGENT; XENOGRAFTS; EFFICACY; TAS-102;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [1] Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.
    Price, Timothy Jay
    Joshi, Rohit
    Karapetis, Christos Stelios
    Cooper, Pam
    Hocking, Chris
    Singhal, Nimit
    Townsend, Amanda Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
    Townsend, Amanda
    Tebbutt, Niall
    Karapetis, Christos
    Cooper, Pamela
    Singhal, Nimit
    Yeend, Susan
    Pirc, Louise
    Joshi, Rohit
    Hardingham, Jennifer
    Price, Timothy
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3838 - 3844
  • [3] Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
    Taniguchi, Hiroya
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Kawakami, Takeshi
    Onozawa, Yusuke
    Honda, Kazunori
    Kadowaki, Shigenori
    Narita, Yukiya
    Tsushima, Takahiro
    Hamauchi, Satoshi
    Todaka, Akiko
    Yokota, Tomoya
    Ando, Masashi
    Mori, Keita
    Shirasu, Hiromichi
    Yasui, Hirofumi
    Muro, Kei
    ONCOLOGIST, 2023, : E1108 - E1113
  • [4] Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
    Kato, Takeshi
    Kagawa, Yoshinori
    Kuboki, Yasutoshi
    Gamoh, Makio
    Komatsu, Yoshito
    Yasui, Hirofumi
    Satake, Hironaga
    Oki, Eiji
    Tanioka, Hiroaki
    Kotaka, Masahito
    Makiyama, Akitaka
    Denda, Tadamichi
    Goto, Masahiro
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Soeda, Junpei
    Shibuya, Kazunori
    Iwata, Masaru
    Oba, Koji
    Yamaguchi, Kensei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1238 - 1247
  • [5] Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
    Takeshi Kato
    Yoshinori Kagawa
    Yasutoshi Kuboki
    Makio Gamoh
    Yoshito Komatsu
    Hirofumi Yasui
    Hironaga Satake
    Eiji Oki
    Hiroaki Tanioka
    Masahito Kotaka
    Akitaka Makiyama
    Tadamichi Denda
    Masahiro Goto
    Takayuki Yoshino
    Kentaro Yamazaki
    Junpei Soeda
    Kazunori Shibuya
    Masaru Iwata
    Koji Oba
    Kensei Yamaguchi
    International Journal of Clinical Oncology, 2021, 26 : 1238 - 1247
  • [6] Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study
    Yamazaki, K.
    Taniguchi, H.
    Masuishi, T.
    Kawakami, T.
    Onozawa, Y.
    Honda, K.
    Tsushima, T.
    Hamauchi, S.
    Mori, K.
    Yasui, H.
    Muro, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S283 - S283
  • [7] First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
    Mendez Mendez, Jose Carlos
    Salgado Fernandez, Mercedes
    de la Camara Gomez, Juan
    Pellon Augusto, Mari Luz
    Covela Rua, Marta
    Quintero Aldana, Guillermo
    Fernandez Montes, Ana
    Reboredo Lopez, Margarida
    Valladares Ayerbes, Manuel
    Jorge Fernandez, Monica
    Gonzalez Villarroel, Paula
    Romero Reinoso, Carlos
    Ramos Vazquez, Manuel
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1263 - 1267
  • [8] A phase II study of trifluridine/tipiracil, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO)
    Gupta, Medhavi
    Fountzilas, Christos
    Vijayvergia, Namrata
    Attwood, Kristopher
    Hochster, Howard S.
    Mukherjee, Sarbajit
    Iyer, Renuka V.
    Boland, Patrick Mckay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope E.
    Morse, Michael A.
    Niedzwiecki, Donna
    Blobe, Gerard C.
    Moyer, Ashley N.
    Bolch, Emily
    Webb, Renee
    Haley, Sherri
    Hatch, Ace J.
    Altomare, Ivy P.
    Sherrill, Gary B.
    Chang, David Z.
    Wells, James L.
    Hsu, S. David
    Jia, Jingquan
    Zafar, S. Yousuf
    Nixon, Andrew B.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2021, 26 (06): : 465 - +
  • [10] A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
    Townsend, A. R.
    Pirc, L.
    Hardingham, J.
    Karapetis, C. S.
    Tebbutt, N. C.
    Singhal, N.
    Price, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345